Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer.

ABSTRACT: Triple-negative breast cancer (TNBC) has poor prognosis with limited treatment options, with little therapeutic progress made during the past several decades. DNA damage response (DDR) associated therapies, including radiation and inhibitors of DDR, demonstrate potential efficacy against TNBC, especially under the guidance of genomic subtype-directed treatment. The tumor immune microenvironment also contributes greatly to TNBC malignancy and response to conventional and targeted therapies. Immunotherapy represents a developing trend in targeted therapies directed against TNBC and strategies combining immunotherapy and modulators of the DDR pathways are being pursued. There is increasing understanding of the potential interplay between DDR pathways and immune-associated signaling. As such,

SUBMITTER: Clark CA 

PROVIDER: S-EPMC8497895 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature